<DOC>
	<DOCNO>NCT00140738</DOCNO>
	<brief_summary>Patients receive maximum 18 injection dHER2 vaccine treatment schedule last year , thereafter follow-up period one year .</brief_summary>
	<brief_title>Safety Immunogenicity Study New dHER2 Vaccine Treat HER2-positive Metastatic Breast Cancer</brief_title>
	<detailed_description>This Phase I/II study conduct accord multicenter , open-label design . At least 20 patient receive vaccine first-line least 20 second-line treatment . The treatment comprise maximum 18 injection dHER2 vaccine . Follow-up phase : This commence end-of-treatment examination , follow examination three month , six month twelve month last study vaccination . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Inclusion criterion : Female . At least 18 year age . Written inform consent participate study . Diagnosis advance breast cancer . Furthermore , patient consider secondline study treatment : The patient receive firstline chemotherapy together Herceptin Herceptin alone metastatic breast disease meeting follow condition : ) For patient receive firstline chemotherapy together Herceptin : The administration chemotherapeutic agent ( ) stop least 3 month , stop least 3 month time first study vaccination , The administration Herceptin alone maintain chemotherapy . ii ) The last dose Herceptin give less 3 week study vaccination . iii ) The patient give Herceptin trial . A tumor lesion patient biopsied screening , show either ) overexpression HER2 protein , determine IHC ( result : IHC 3+ ) , ii ) amplification HER2 gene determine FISH ( least 4fold , i.e. , least 8 copy ) . For patient consider firstline study treatment : The patient 's metastatic disease affect skin and/or lymph node and/or lung , organ ( exception asymptomatic bone lesion ) . For patient consider secondline study treatment : The patient 's metastatic disease may affect organ ( ) exception central nervous system ( CNS ) . At least one measurable lesion . ECOG status 0 1 . Agree use effective contraception duration study statement plan bear child future . Result serum Î²HCG pregnancy test screen visit negative . ( This apply patient childbearing potential ) Adequate bone marrow reserve . Adequate renal function . Adequate hepatic function . Baseline LVEF measure MUGA scan equal great low limit normal radiology facility . Results viral screening test ( HCV , HBV surface antigen ) sample take screen visit negative . Investigator believe patient comply requirement protocol . The following condition applies center France : A subject eligible inclusion study he/she either affiliated beneficiary social security category . It investigator 's responsibility ensure document ( source document patient note ) patient either affiliate beneficiary social security category . Exclusion criterion : For patient consider firstline study treatment : Received chemotherapy metastatic breast disease . Received &gt; 300 mg/m2 doxorubicin ( cumulative dose ) &gt; 600 mg/m2 epirubicin ( cumulative dose ) . Although hormone therapy firstline therapy metastatic disease accept , must NOT start modify ( nature dosage ) within 12 week first study vaccination , NO change study period may anticipate . Treatment bisphosphonate UNLESS bisphosphonate treatment initiate 3 month first study vaccination . Received investigational nonregistered drug vaccine study vaccine within 30 day precede first dose study vaccine , plan receive drug study period . For patient consider firstline study treatment , follow result exclusion patient : 1 . Any organ skin , lymph node , bone lung affect metastatic disease . 2 . If lung affect : &gt; 3 lung lesion detect . 3 . If lung affect : Any lesion measure 30 mm ( long diameter ) . 4 . If lung affect : The lung metastases cause functional impairment . 5 . The sponsor may study instruct sit patient lung metastasis include . Receipt instruction sponsor constitutes exclusion criterion patient lung metastases.For patient consider secondline study treatment , presence lung metastasis cause functional impairment follow result exclusion patient . The patient history congestive heart failure difficulttocontrol hypertension , hypercholesterolemia diabetes . The patient know coronary artery disease , arrhythmia require treatment , clinically significant valvular disease , cardiomegaly chest Xray , ventricular hypertrophy ( find ECG ) previous myocardial infarction . The patient acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination laboratory screen test . The patient present autoimmune disease . The patient require chronic administration immunosuppressive drug include corticosteroid . Medical history include splenectomy irradiation spleen . Known family history congenital hereditary immunodeficiency . Received major organ graft ( include bonemarrow transplantation ) . Any uncontrolled bleeding disorder coagulation disorder thrombocytopenia prothrombotic disorder . History anaphylaxis severe allergic reaction vaccine unknown allergen . HIV positive . Previous concomitant malignancy site , except ( ) effectively treat nonmelanoma skin cancer carcinoma situ cervix , ( ii ) effectively treat malignancy remission &gt; 2 year consider highly likely cure . Pregnant lactating . Any psychiatric addictive disorder may compromise ability give informed consent , comply trial procedure . Any history alcohol drug abuse . Any condition present opinion investigator might jeopardize patient 's safety ability comply requirement study Received commercial vaccine within one week first study vaccination .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>